Immunological Evaluation and Comparison of Different EV71 Vaccine Candidates
Autor: | Suh-Chin Wu, Chia-Chyi Liu, Min Shi Lee, Jen Ren Wang, Yen Hung Chow, Kuang Nan Hsiao, Shu Pei Lien, Jui Yuan Chang, Shih Jen Liu, Charles Sia, Chia Hsin Hsiao, Pele Chong, Ai Hsiang Chou, Meng Shin Guo, Hau Pong Tasi |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2012 |
Předmět: |
lcsh:Immunologic diseases. Allergy
Article Subject viruses Immunology Antibodies Viral Cell Line Mice Antigen Cell Line Tumor Chlorocebus aethiops Rhabdomyosarcoma Enterovirus Infections Virus-neutralizing Antibody Enterovirus 71 Animals Immunology and Allergy Vero Cells Viral Structural Proteins Neurotropic virus Mice Inbred BALB C Vaccines Synthetic biology Immunogenicity Viral Vaccine Virion virus diseases Viral Vaccines General Medicine Viral Load biology.organism_classification Antibodies Neutralizing Virology Peptide Fragments Enterovirus A Human Titer biology.protein Capsid Proteins Female Rabbits Antibody lcsh:RC581-607 Research Article |
Zdroj: | Clinical and Developmental Immunology, Vol 2012 (2012) Clinical and Developmental Immunology |
ISSN: | 1740-2530 1740-2522 |
Popis: | Enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) are major causative agents of hand, foot, and mouth diseases (HFMDs), and EV71 is now recognized as an emerging neurotropic virus in Asia. Effective medications and/or prophylactic vaccines against HFMD are not available. The current results from mouse immunogenicity studies using in-house standardized RD cell virus neutralization assays indicate that (1) VP1 peptide (residues 211–225) formulated with Freund’s adjuvant (CFA/IFA) elicited low virus neutralizing antibody response (1/32 titer); (2) recombinant virus-like particles produced from baculovirus formulated with CFA/IFA could elicit good virus neutralization titer (1/160); (3) individual recombinant EV71 antigens (VP1, VP2, and VP3) formulated with CFA/IFA, only VP1 elicited antibody response with 1/128 virus neutralization titer; and (4) the formalin-inactivated EV71 formulated in alum elicited antibodies that cross-neutralized different EV71 genotypes (1/640), but failed to neutralize CVA16. In contrast, rabbits antisera could cross-neutralize strongly against different genotypes of EV71 but weakly against CVA16, with average titers 1/6400 and 1/32, respectively. The VP1 amino acid sequence dissimilarity between CVA16 and EV71 could partially explain why mouse antibodies failed to cross-neutralize CVA16. Therefore, the best formulation for producing cost-effective HFMD vaccine is a combination of formalin-inactivated EV71 and CAV16 virions. |
Databáze: | OpenAIRE |
Externí odkaz: |